Skip to main content
Top
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Gastric Cancer | Primary research

Long noncoding RNA LBX2-AS1-modulated miR-4766-5p regulates gastric cancer development through targeting CXCL5

Authors: LiPan Peng, ZeZhong Chen, GuangChuan Wang, ShuBo Tian, Shuai Kong, Tao Xu, XiaoHua An, YueZhi Chen

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Long noncoding RNAs (LncRNAs) have been reported to critically regulate gastric cancer (GC). Recently, it was reported that LBX2 antisense RNA 1 (LBX2-AS1) is abnormally expressed in GC. However, the role of LBX2-AS1 in the malignancy of GC is worth further discussion.

Methods

Quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine the LBX2-AS1, miR-4766-5p and C-X-C motif chemokine (CXCL5) expression in GC tissues and cells. Dual-luciferase reporter assay was applied to examine the target relationship between LBX2-AS1 and miR-4766-5p or miR-4766-5p and CXCL5. Cell counting kit-8 (CCK-8) and Transwell assays were used to detect cell proliferation, migration and invasion rates. The protein expression of CXCL5 was confirmed using western blot. The RNA pull down experiment was used to verify the specificity of LBX2-AS1 and miR-4766-5p on BGC-823 and SGC-7901 cells.

Results

LBX2-AS1 was up-regulated in GC tissues and cells, and its knockdown suppressed proliferation, migration and invasion of GC cells. While, overexpression of LBX2-AS1 increased proliferation and increased CXCL5 mRNA level. CXCL5 improved cell proliferation, migration and invasion of GC cells. LBX2-AS1 could bind to miR-4766-5p to regulate CXCL5 expression. Overexpression of CXCL5 overturned those effects of miR-4766-5p in GC cells. RNA Pull down shown that BGC-823 and SGC-7901 cells, miR-4766-5p specifically binds to LBX2-AS1.

Conclusions

In short, this study demonstrated that LBX2-AS1 promoted proliferation, migration and invasion through up-regulation CXCL5 mediated by miR-4766-5p in GC. The LBX2-AS1/miR-4766-5p/CXCL5 regulatory axis provides a theoretical basis for the research on lncRNA-directed therapeutics in GC.
Literature
1.
go back to reference Wang F, Tang C, Xu D, Tang Y, Jiang Y, Gao X, Xu J. LncRNA ADAMTS9-AS2 suppresses the proliferation of gastric cancer cells and the tumorigenicity of cancer stem cells through regulating SPOP. J Cell Mol Med. 2020;24(8):4830–8.CrossRef Wang F, Tang C, Xu D, Tang Y, Jiang Y, Gao X, Xu J. LncRNA ADAMTS9-AS2 suppresses the proliferation of gastric cancer cells and the tumorigenicity of cancer stem cells through regulating SPOP. J Cell Mol Med. 2020;24(8):4830–8.CrossRef
2.
go back to reference Ryun Park S. Management of gastric cancer: East vs West. Curr Probl Cancer. 2015;39(6):315–41.CrossRef Ryun Park S. Management of gastric cancer: East vs West. Curr Probl Cancer. 2015;39(6):315–41.CrossRef
3.
4.
go back to reference Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143–57.CrossRef Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143–57.CrossRef
5.
go back to reference Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16(3):167–79.CrossRef Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16(3):167–79.CrossRef
6.
go back to reference Wang Y, Zhao Y, Zhang X, Zhang A, Ma J. Long noncoding RNA LBX2-AS1 drives the progression of hepatocellular carcinoma by sponging microRNA-384 and thereby positively regulating IRS1 expression. Pathol Res Pract. 2020;216(4):152903–3.CrossRef Wang Y, Zhao Y, Zhang X, Zhang A, Ma J. Long noncoding RNA LBX2-AS1 drives the progression of hepatocellular carcinoma by sponging microRNA-384 and thereby positively regulating IRS1 expression. Pathol Res Pract. 2020;216(4):152903–3.CrossRef
7.
go back to reference Tang LX, Su SF, Wan Q, He P, Xhang Y, Cheng XM. Novel long non-coding RNA LBX2-AS1 indicates poor prognosis and promotes cell proliferation and metastasis through Notch signaling in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2019;23(17):7419–29.PubMed Tang LX, Su SF, Wan Q, He P, Xhang Y, Cheng XM. Novel long non-coding RNA LBX2-AS1 indicates poor prognosis and promotes cell proliferation and metastasis through Notch signaling in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2019;23(17):7419–29.PubMed
8.
go back to reference Yang Z, Dong X, Pu M, Yang H, Chang W, Ji F, Liu T, Wei C, Zhang X, Qiu X. LBX2-AS1/miR-219a-2-3p/FUS/LBX2 positive feedback loop contributes to the proliferation of gastric cancer. Gastric Cancer. 2019;23(3):449–63. CrossRef Yang Z, Dong X, Pu M, Yang H, Chang W, Ji F, Liu T, Wei C, Zhang X, Qiu X. LBX2-AS1/miR-219a-2-3p/FUS/LBX2 positive feedback loop contributes to the proliferation of gastric cancer. Gastric Cancer. 2019;23(3):449–63. CrossRef
9.
go back to reference Liang Y, Song X, Li Y, Sang Y, Zhang N, Zhang H, Liu Y, Duan Y, Chen B, Guo R, et al. A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis. 2018;9(5):563. CrossRef Liang Y, Song X, Li Y, Sang Y, Zhang N, Zhang H, Liu Y, Duan Y, Chen B, Guo R, et al. A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis. 2018;9(5):563. CrossRef
10.
go back to reference Zhan W, Liao X, Chen Z, Li L, Tian T, Yu L, Li R. LINC00858 promotes colorectal cancer by sponging miR-4766-5p to regulate PAK2. Cell Biol Toxicol. 2020;36(4):333–47. CrossRef Zhan W, Liao X, Chen Z, Li L, Tian T, Yu L, Li R. LINC00858 promotes colorectal cancer by sponging miR-4766-5p to regulate PAK2. Cell Biol Toxicol. 2020;36(4):333–47. CrossRef
11.
go back to reference Wei Y, Wang Y, Zang A, Wang Z, Fang G, Hong D. MiR-4766-5p inhibits the development and progression of gastric cancer by targeting NKAP. OncoTargets Ther. 2019;12:8525–36. CrossRef Wei Y, Wang Y, Zang A, Wang Z, Fang G, Hong D. MiR-4766-5p inhibits the development and progression of gastric cancer by targeting NKAP. OncoTargets Ther. 2019;12:8525–36. CrossRef
12.
go back to reference Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH, Feng H, Zheng MH, Zhao JK, Lu AG. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-kappaB pathway in colorectal cancer. Cell Death Dis. 2019;10(3):178.CrossRef Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH, Feng H, Zheng MH, Zhao JK, Lu AG. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-kappaB pathway in colorectal cancer. Cell Death Dis. 2019;10(3):178.CrossRef
13.
go back to reference Ando Y, Ohuchida K. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. PLoS ONE. 2020;15(1):e0228015. CrossRef Ando Y, Ohuchida K. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. PLoS ONE. 2020;15(1):e0228015. CrossRef
14.
go back to reference Liu G, Yang ZF, Zhou PY, Zhou C, Guan RY, Sun BY, Fan J, Zhou J, Yi Y, Qiu SJ. ROR-alpha-1 inhibits the proliferation, invasion, and migration of hepatocellular carcinoma MHCC97H via downregulation of chemokine CXCL5. Cytokine. 2020;129:155004.CrossRef Liu G, Yang ZF, Zhou PY, Zhou C, Guan RY, Sun BY, Fan J, Zhou J, Yi Y, Qiu SJ. ROR-alpha-1 inhibits the proliferation, invasion, and migration of hepatocellular carcinoma MHCC97H via downregulation of chemokine CXCL5. Cytokine. 2020;129:155004.CrossRef
15.
go back to reference Park JY, Park KH, Bang S, Kim MH, Lee JE, Gang J, Koh SS, Song SY. CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol. 2007;133(11):835–40.CrossRef Park JY, Park KH, Bang S, Kim MH, Lee JE, Gang J, Koh SS, Song SY. CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol. 2007;133(11):835–40.CrossRef
16.
go back to reference Gu X, Gong H, Shen L, Gu Q. MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A. American journal of translational research. 2018;10(9):2834–47.PubMedPubMedCentral Gu X, Gong H, Shen L, Gu Q. MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A. American journal of translational research. 2018;10(9):2834–47.PubMedPubMedCentral
17.
go back to reference Strong VE, Wu A-W, Selby LV, Gonen M, Hsu M, Song KY, Park CH, Coit DG, Ji J-F, Brennan MF. Differences in gastric cancer survival between the U.S. and China. J Surg Oncol. 2015;112(1):31–7.CrossRef Strong VE, Wu A-W, Selby LV, Gonen M, Hsu M, Song KY, Park CH, Coit DG, Ji J-F, Brennan MF. Differences in gastric cancer survival between the U.S. and China. J Surg Oncol. 2015;112(1):31–7.CrossRef
18.
go back to reference Im MH, Kim JW, Kim WS, Kim JH, Youn YH, Park H, Choi SH. The Impact of Esophageal Reflux-Induced Symptoms on Quality of Life after Gastrectomy in Patients with Gastric Cancer. J Gastric Cancer. 2014;14(1):15–22.CrossRef Im MH, Kim JW, Kim WS, Kim JH, Youn YH, Park H, Choi SH. The Impact of Esophageal Reflux-Induced Symptoms on Quality of Life after Gastrectomy in Patients with Gastric Cancer. J Gastric Cancer. 2014;14(1):15–22.CrossRef
19.
go back to reference Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253–61. CrossRef Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253–61. CrossRef
20.
go back to reference Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer research. 2017;77(15):3965–81. CrossRef Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer research. 2017;77(15):3965–81. CrossRef
21.
go back to reference Hu BW, Fan HQ, Lv X. C SF, SZW: Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis. Cancer Cell Int. 2018;18:68.CrossRef Hu BW, Fan HQ, Lv X. C SF, SZW: Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis. Cancer Cell Int. 2018;18:68.CrossRef
22.
go back to reference Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res. 2006;66(8):4279–84.CrossRef Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res. 2006;66(8):4279–84.CrossRef
23.
go back to reference Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;56(6):2242–54.CrossRef Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology. 2012;56(6):2242–54.CrossRef
24.
go back to reference Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y, Kusunoki M. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer. 2012;48(14):2244–51.CrossRef Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y, Kusunoki M. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer. 2012;48(14):2244–51.CrossRef
Metadata
Title
Long noncoding RNA LBX2-AS1-modulated miR-4766-5p regulates gastric cancer development through targeting CXCL5
Authors
LiPan Peng
ZeZhong Chen
GuangChuan Wang
ShuBo Tian
Shuai Kong
Tao Xu
XiaoHua An
YueZhi Chen
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01579-z

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine